Fast Five Quiz: COVID-19 Clinical Keys

Michael Stuart Bronze, MD

Disclosures

October 22, 2020

According to IDSA guidelines on the diagnosis of COVID-19, a SARS-CoV-2 nucleic acid amplification test is recommended in symptomatic individuals suspected of having COVID-19, even when the clinical suspicion for COVID-19 is low.

The IDSA suggests collecting nasopharyngeal, mid-turbinate, or nasal swabs rather than oropharyngeal swabs or saliva alone for SARS-CoV-2 RNA testing in symptomatic individuals with upper respiratory tract infection or influenza-like illness suspected of having COVID-19.

The IDSA suggests initially obtaining an upper respiratory tract sample (eg, nasopharyngeal swab) rather than a lower respiratory sample for SARS-CoV-2 RNA testing in hospitalized patients with suspected COVID-19 lower respiratory tract infection. If the initial upper respiratory sample result is negative and suspicion for disease remains high, the IDSA suggests collecting a lower respiratory tract sample (eg, sputum, bronchoalveolar lavage fluid, tracheal aspirate) rather than collecting another upper respiratory sample.

The IDSA recommends repeat viral RNA testing when the initial test is negative (vs performing a single test) in symptomatic individuals with an intermediate or high clinical suspicion of COVID-19.

The IDSA recommends SARS-CoV-2 RNA testing in immunocompromised, asymptomatic individuals who are being admitted to the hospital, regardless of exposure to COVID-19.

Read more about the diagnosis of COVID-19.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....